Table 3.
Treatment characteristics
| N (%) or mean (SD) or median (IQR) | Overall (N=27) |
Early-Stage NSCLC (N=13) |
Locally Recurrent NSCLC (N=3) |
Metastatic Disease (N=11) |
|---|---|---|---|---|
| Proton SBRT Details | ||||
| Total dose, CGyE | ||||
| Mean (SD) | 46.9 (10.7) | 50.7 (2.7) | 43.3 (11.5) | 43.4 (14.8) |
| Median (IQR) | 50 (45-50) | 50 (50-50) | 50 (30-N/A) | 45 (27.8-60) |
| BED10, CGyE | ||||
| Mean (SD) | 91.0 (24.8) | 100.4 (1.3) | 82.7 (30.0) | 82.1 (34.3) |
| Median (IQR) | 100 (86-100) | 100 (100-100) | 100 (48-N/A) | 86 (48.8-105) |
| Number of fractions | ||||
| Median (IQR) | 5 (5-5) | 5 (5-5) | 5 (5-N/A) | 5 (5-5) |
| Mode | 5 | 5 | 5 | 5 |
| Treatment schedule | ||||
| Daily | 17 (58.6%) | 8 (57.1%) | 2 (66.7%) | 7 (58.3%) |
| Every other day | 11 (37.9%) | 5 (35.7%) | 1 (33.3%) | 5 (41.7%) |
| Other | 1 (3.4%) | 1 (7.1%) | 0 (0%) | 0 (0%) |